Micro-Rna Expression Abnormalities of Pancreatic, Endocrine and Acinar Tumors
AssigneeThe Ohio State University
InventorsCarlo M. Croce, George A. Calin
Life of this patent
Estimating the term…
Abstract
The present invention provides novel methods and compositions for the diagnosis, prognosis and treatment of pancreatic cancer. The invention also provides methods of identifying anti-pancreatic cancer agent.
Claims64
A method of diagnosing whether a subject has, or is at risk for developing, pancreatic cancer, comprising measuring the level of at least one miR gene product in a test sample from said subject, wherein an alteration in the level of the miR gene product in the test sample, relative to the level of a corresponding miR gene product in a control sample, is indicative of the subject either having, or being at risk for developing, pancreatic cancer.
A method of diagnosing whether a subject has, or is at risk for developing, pancreatic acinar cell carcinoma (PACC), comprising measuring the level of at least one miR gene product in a test sample from said subject, wherein an alteration in the level of the miR gene product in the test sample, relative to the level of a corresponding miR gene product in a control sample, is indicative of the subject either having, or being at risk for developing, PACC.
A method of diagnosing the type of pancreatic cancer that a subject has, comprising measuring the level of at least one miR gene product in a test sample from said subject, wherein an alteration in the level of the miR gene product in the test sample, relative to the level of a corresponding miR gene product in a control sample, is indicative of the type of pancreatic cancer.
A method of determining the prognosis of a subject with pancreatic cancer, comprising measuring the level of at least one miR gene product in a test sample from said subject, wherein:
- the miR gene product is associated with an adverse prognosis in pancreatic cancer;
- and
- an alteration in the level of the at least one miR gene product in the test sample, relative to the level of a corresponding miR gene product in a control sample, is indicative of an adverse prognosis.
A method of determining whether a pancreatic cancer in a subject is metastatic, comprising measuring the level of at least one miR gene product in a test sample from said subject, wherein:
- the miR gene product is associated with metastasis;
- and
- an alteration in the level of the at least one miR gene product in the test sample, relative to the level of a corresponding miR gene product in a control sample, is indicative of metastasis.
A method of determining whether a pancreatic cancer in a subject has a high proliferation index, comprising measuring the level of at least one miR gene product in a test sample from said subject, wherein:
- the miR gene product is associated with a high proliferation index;
- and
- an alteration in the level of the at least one miR gene product in the test sample, relative to the level of a corresponding miR gene product in a control sample, is indicative of a high proliferation index.
A method of determining the prognosis of a subject with pancreatic cancer, comprising measuring the level of PDCD4 in a test sample from said subject, wherein an alteration in the level of PDCD4 in the test sample, relative to the level of a corresponding miR gene product in a control sample, is indicative of an adverse prognosis.
A method of diagnosing whether a subject has, or is at risk for developing, pancreatic cancer, comprising:
- (1) reverse transcribing RNA from a test sample obtained from the subject to provide a set of target oligodeoxynucleotides;
- (2) hybridizing the target oligodeoxynucleotides to a microarray comprising miRNA-specific probe oligonucleotides to provide a hybridization profile for the test sample;
- and
- (3) comparing the test sample hybridization profile to a hybridization profile generated from a control sample,
- wherein an alteration in the signal of at least one miRNA is indicative of the subject either having, or being at risk for developing, pancreatic cancer.
A method of diagnosing whether a subject has, or is at risk for developing, a pancreatic cancer with an adverse prognosis, comprising:
- (1) reverse transcribing RNA from a test sample obtained from the subject to provide a set of target oligodeoxynucleotides;
- (2) hybridizing the target oligodeoxynucleotides to a microarray comprising miRNA-specific probe oligonucleotides to provide a hybridization profile for said test sample;
- and
- (3) comparing the test sample hybridization profile to a hybridization profile generated from a control sample,
- wherein an alteration in the signal is indicative of the subject either having, or being at risk for developing, a pancreatic cancer with an adverse prognosis.
A method of treating pancreatic cancer in a subject who has a pancreatic cancer in which at least one miR gene product is downregulated or upregulated in the cancer cells of the subject relative to control cells, comprising:
- (1) when the at least one miR gene product is downregulated in the cancer cells, administering to the subject an effective amount of at least one isolated miR gene product, or an isolated variant or biologically-active fragment thereof, provided that the miR gene product is not miR-15a or miR-16-1, such that proliferation of cancer cells in the subject is inhibited;
- or
- (2) when the at least one miR gene product is upregulated in the cancer cells, administering to the subject an effective amount of at least one compound for inhibiting expression of the at least one miR gene product, such that proliferation of cancer cells in the subject is inhibited.
A method of treating pancreatic cancer in a subject, comprising:
- (1) determining the amount of at least one miR gene product in pancreatic cancer cells, relative to control cells;
- and
- (2) altering the amount of miR gene product expressed in the pancreatic cancer cells by:
- (i) administering to the subject an effective amount of at least one isolated miR gene product, or an isolated variant or biologically-active fragment thereof, provided that the miR gene product is not miR-15a or miR-16-1, if the amount of the miR gene product expressed in the cancer cells is less than the amount of the miR gene product expressed in control cells;
- or
- (ii) administering to the subject an effective amount of at least one compound for inhibiting expression of the at least one miR gene product, if the amount of the miR gene product expressed in the cancer cells is greater than the amount of the miR gene product expressed in control cells.
A pharmaceutical composition for treating pancreatic cancer, comprising at least one isolated miR gene product, or an isolated variant or biologically-active fragment thereof, and a pharmaceutically-acceptable carrier.
A pharmaceutical composition for treating pancreatic cancer, comprising at least one miR expression-inhibitor compound and a pharmaceutically-acceptable carrier.
A method of identifying an anti-pancreatic cancer agent, comprising providing a test agent to a cell and measuring the level of at least one miR gene product associated with decreased expression levels in pancreatic cancer cells, wherein an increase in the level of the miR gene product in the cell, relative to a control cell, is indicative of the test agent being an anti-pancreatic cancer agent.
A method of identifying an anti-pancreatic cancer agent, comprising providing a test agent to a cell and measuring the level of at least one miR gene product associated with increased expression levels in pancreatic cancer cells, wherein a decrease in the level of the miR gene product in the cell, relative to a control cell, is indicative of the test agent being an anti-pancreatic cancer agent.
Dependencies are inferred from the claim text.